NCT04405401

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.

Conditions

• Lung Cancer Metastatic

Interventions

Type	Name	Description
RADIATION	SABR	SABR to all oligoprogressive lesions + continuation of current systemic therapy
OTHER	Standard of care	Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.

Timeline

• Start date: 2021-01-05
• Primary completion: 2025-07-01
• Completion: 2027-07-01
• First posted: 2020-05-28
• Last updated: 2023-12-12

Locations

1 site across 1 country: Canada